Form 4: QuidelOrtho CTO Siegrist Reports RSU Vesting, Tax Sale

QuidelOrtho's EVP of R&D & CTO, Jonathan Philip Siegrist, reported the vesting of 2,448 restricted stock units and a subsequent sale of 1,009 shares for tax obligations.

Summary

• Jonathan Philip Siegrist, EVP of R&D & CTO of QuidelOrtho Corp (QDEL), reported transactions on January 29, 2026.
• Siegrist acquired 2,448 shares of common stock upon the vesting of previously reported restricted stock units.
• Concurrently, Siegrist disposed of 1,009 shares of common stock at a price of $27.41 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Siegrist directly beneficially owns 13,419 shares of common stock.
• Additionally, 4,898 restricted stock units remain, with future vesting scheduled for January 29, 2027, and January 29, 2028, in equal installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax management rather than a significant change in company fundamentals or executive sentiment.

Positives

• The vesting of 2,448 restricted stock units indicates a successful milestone for the executive, converting equity awards into common stock.
• The executive retains a significant number of shares (13,419 common shares and 4,898 RSUs), demonstrating continued alignment with shareholder interests.

Negatives

• The disposition of 1,009 shares for tax withholding purposes reduces the executive's direct common stock holdings.

Future Outlook

The filing indicates future vesting events for 4,898 restricted stock units, with equal installments scheduled for January 29, 2027, and January 29, 2028.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing RSU vesting and tax-related sales, are common occurrences for executives in the biotechnology and diagnostics industry. These transactions typically reflect pre-scheduled compensation events rather than discretionary trading based on new material information.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of executives receiving restricted stock units as part of their compensation package and subsequently selling a portion to cover tax obligations upon vesting is a standard industry practice across publicly traded companies, including those in the medical diagnostics sector like QuidelOrtho.
• Comparable companies such as Abbott Laboratories (ABT) and Danaher Corporation (DHR) also frequently report similar executive RSU vesting and tax-related dispositions in their Form 4 filings, reflecting common equity compensation structures.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine executive compensation event. The executive's continued equity holdings align interests.

Next Steps

• Remaining 4,898 restricted stock units will vest in equal installments on January 29, 2027.
• Remaining 4,898 restricted stock units will vest in equal installments on January 29, 2028.

Key Dates

Keywords

QuidelOrtho, QDEL, Jonathan Philip Siegrist, Form 4, insider trading, restricted stock units, RSU vesting, common stock, executive compensation, tax withholding